Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 23219426)

1.

Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer.

Li CR, Su JJ, Wang WY, Lee MT, Wang TY, Jiang KY, Li CF, Hsu JM, Chen CK, Chen M, Jiang SS, Weaver VM, Tsai KK.

Am J Pathol. 2013 Feb;182(2):363-74. doi: 10.1016/j.ajpath.2012.10.024. Epub 2012 Dec 4.

2.

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA.

J Clin Invest. 2008 Aug;118(8):2711-21. doi: 10.1172/JCI34780.

3.

Prostate-specific Klf6 inactivation impairs anterior prostate branching morphogenesis through increased activation of the Shh pathway.

Leow CC, Wang BE, Ross J, Chan SM, Zha J, Carano RA, Frantz G, Shen MM, de Sauvage FJ, Gao WQ.

J Biol Chem. 2009 Jul 31;284(31):21057-65. doi: 10.1074/jbc.M109.001776. Epub 2009 Jun 3. Erratum in: J Biol Chem. 2011 Dec 16;286(50):43587.

4.

Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.

Bismar TA, Alshalalfa M, Petersen LF, Teng LH, Gerke T, Bakkar A, Al-Mami A, Liu S, Dolph M, Mucci LA, Alhajj R.

BJU Int. 2014 Feb;113(2):309-19. doi: 10.1111/bju.12262. Epub 2013 Sep 5.

PMID:
24006850
5.

Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.

Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, Riedmiller H, Kneitz B.

PLoS One. 2013 Jun 14;8(6):e65064. doi: 10.1371/journal.pone.0065064. Print 2013.

6.

Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma.

Che JP, Li W, Yan Y, Liu M, Wang GC, Li QY, Yang B, Yao XD, Zheng JH.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2300-11. eCollection 2013.

7.

Effect of ionizing radiation on acinar morphogenesis of human prostatic epithelial cells under three-dimensional culture conditions.

Wang T, X SM, Kong D, Yi H, Wang X, Liang B, Xu H, He M, Jia L, Qased AB, Yang Y, Liu X.

Neoplasma. 2012;59(3):269-81. doi: 10.4149/neo_2012_035.

PMID:
22296497
8.

Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.

Le Magnen C, Bubendorf L, Ruiz C, Zlobec I, Bachmann A, Heberer M, Spagnoli GC, Wyler S, Mengus C.

Eur J Cancer. 2013 Mar;49(4):955-63. doi: 10.1016/j.ejca.2012.09.023. Epub 2012 Oct 22.

PMID:
23089465
9.

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.

Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB.

PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013.

10.

Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer.

Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, Gallucci M, De Carli P, Sentinelli S, Cianciulli AM, Mottolese M, Carlini P, Arcelli D, Helmer-Citterich M, Gaetano C, Loda M, Pontecorvi A, Bacchetti S, Sacchi A, Farsetti A.

Mol Cancer Res. 2006 Feb;4(2):79-92.

11.

A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.

Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MT, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL, Chen LT, Tsai KK.

Gastroenterology. 2013 Nov;145(5):1110-20. doi: 10.1053/j.gastro.2013.07.040. Epub 2013 Jul 27.

PMID:
23896173
12.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

PMID:
24836057
13.

Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.

Nariculam J, Freeman A, Bott S, Munson P, Cable N, Brookman-Amissah N, Williamson M, Kirby RS, Masters J, Feneley M.

Asian J Androl. 2009 Jan;11(1):109-18. doi: 10.1038/aja.2008.22. Epub 2008 Dec 1.

14.

Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers.

Chiam K, Ryan NK, Ricciardelli C, Day TK, Buchanan G, Ochnik AM, Murti K, Selth LA; Australian Prostate Cancer BioResource, Butler LM, Tilley WD, Bianco-Miotto T.

Prostate. 2013 Jan;73(2):182-93. doi: 10.1002/pros.22554. Epub 2012 Jul 10.

PMID:
22782870
15.

Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells.

Webber MM, Bello D, Kleinman HK, Hoffman MP.

Carcinogenesis. 1997 Jun;18(6):1225-31.

16.

Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.

Rajan P, Stockley J, Sudbery IM, Fleming JT, Hedley A, Kalna G, Sims D, Ponting CP, Heger A, Robson CN, McMenemin RM, Pedley ID, Leung HY.

BMC Cancer. 2014 Dec 18;14:977. doi: 10.1186/1471-2407-14-977.

17.

Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.

Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K.

Eur Urol. 2007 May;51(5):1259-66. Epub 2006 Jun 14.

PMID:
16806661
18.

Expression of SOCSs in human prostate cancer and their association in prognosis.

Zhu JG, Dai QS, Han ZD, He HC, Mo RJ, Chen G, Chen YF, Wu YD, Yang SB, Jiang FN, Chen WH, Sun ZL, Zhong WD.

Mol Cell Biochem. 2013 Sep;381(1-2):51-9. doi: 10.1007/s11010-013-1687-6. Epub 2013 May 11.

PMID:
23666742
19.

A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.

Thompson VC, Day TK, Bianco-Miotto T, Selth LA, Han G, Thomas M, Buchanan G, Scher HI, Nelson CC; Australian Prostate Cancer BioResource, Greenberg NM, Butler LM, Tilley WD.

Int J Cancer. 2012 Aug 1;131(3):662-72. doi: 10.1002/ijc.26414. Epub 2012 Jan 24.

PMID:
22275114
20.

Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.

Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D.

Clin Cancer Res. 2005 Dec 1;11(23):8321-5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk